ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,001 to 1,020 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Vitamins vs Placebo: Hematocrit ≤24% With Transfusion40 of 4,954

59 of 4,927

-0.4 points

-0.8 to 0.0

9,881NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Postpartum Pulmonary Edema3 of 4,951

10 of 4,926

-0.1 points

-0.3 to 0.0

9,877NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

S-268019-b vs Placebo: Number of Participants With First Occurrence of SARS-CoV-2 RT-PCR-Positive Severe COVID-19 in the Initial Vaccination Period Regardless of Serostatus or PCR Status at Baseline0 of 6,581

1 of 3,285

-0.0 points

-0.2 to 0.0

9,866NCT05212948

A Study of S-268019 for the Prevention of COVID-19

S-268019-b vs Placebo: Number of Participants With First Occurrence of SARS-CoV-2 RT-PCR-Positive Symptomatic COVID-19 in the Initial Vaccination Period Regardless of Serostatus or PCR Status at Baseline479 of 6,579

324 of 3,285

-2.6 points

-3.8 to -1.4

9,864NCT05212948

A Study of S-268019 for the Prevention of COVID-19

Vitamins vs Placebo: Premature Rupture of Membranes124 of 4,934

129 of 4,923

-0.1 points

-0.7 to 0.5

9,857NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Sertindole vs Risperidone: Number of Participants With Suicide Attempts (Fatal and Non-fatal) - MedDRA43 of 4,905

65 of 4,904

-0.4 points

-0.9 to -0.0

9,809NCT00856583

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Cardiac Deaths - MedDRA17 of 4,905

8 of 4,904

0.2 points

-0.0 to 0.4

9,809NCT00856583

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Cardiac Deaths - ISC31 of 4,905

12 of 4,904

0.4 points

0.1 to 0.7

9,809NCT00856583

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Completed Suicides - MedDRA13 of 4,905

21 of 4,904

-0.2 points

-0.4 to 0.1

9,809NCT00856583

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Sertindole vs Risperidone: Number of Participants With Suicide Attempts (Fatal and Non-fatal) - ISC68 of 4,905

76 of 4,904

-0.2 points

-0.6 to 0.3

9,809NCT00856583

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - MedDRA34 of 4,905

32 of 4,904

0.0 points

-0.3 to 0.4

9,809NCT00856583

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Sertindole vs Risperidone: Number of Participants With Discontinuation of Treatment for Any Reason Other Than Study Closure3,136 of 4,905

2,597 of 4,904

11.0 points

9.0 to 12.9

9,809NCT00856583

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Sertindole vs Risperidone: Number of Participants With Hospitalisations, Excluding Hospitalisations Related to the Primary Psychiatric Disease174 of 4,905

149 of 4,904

0.5 points

-0.2 to 1.2

9,809NCT00856583

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Sertindole vs Risperidone: Second Primary Outcome: Number of Participants With Cardiac Events, Including Arrhythmias, Requiring Hospitalisation10 of 4,905

6 of 4,904

0.1 points

-0.1 to 0.3

9,809NCT00856583

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - ISC19 of 4,905

28 of 4,904

-0.2 points

-0.5 to 0.1

9,809NCT00856583

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Completed Suicides - ISC14 of 4,905

21 of 4,904

-0.1 points

-0.4 to 0.1

9,809NCT00856583

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Sertindole vs Risperidone: serious adverse events266 of 4,905

217 of 4,904

1.0 points

0.1 to 1.9

9,809NCT00856583

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

Randomized Sibutramine vs Randomized Placebo: Risk of Experiencing Cardiovascular Death Included in the POE223 of 4,906

229 of 4,898

-0.1 points

-1.0 to 0.7

9,804NCT00234832

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients

Randomized Sibutramine vs Randomized Placebo: Risk of Experiencing a Nonfatal MI Included in the POE200 of 4,906

159 of 4,898

0.8 points

0.1 to 1.6

9,804NCT00234832

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients

Randomized Sibutramine vs Randomized Placebo: Risk of Experiencing a Nonfatal Stroke Included in the POE127 of 4,906

95 of 4,898

0.6 points

0.1 to 1.2

9,804NCT00234832

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=51

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00135707-e8bbd0ff",
        "title": "Vitamins vs Placebo: Hematocrit ≤24% With Transfusion",
        "summary": "40 of 4954 against 59 of 4927; risk difference -0.4 points, 95% interval -0.8 to 0.0; NCT00135707, Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)",
        "record": "/library/comparisons/NCT00135707-e8bbd0ff",
        "nct_id": "NCT00135707",
        "kind": "outcome",
        "participants": 9881,
        "risk_difference": {
          "value": -0.0039005491479598906,
          "lower": -0.007951271735701978,
          "upper": 0.0000487861100292317
        },
        "group_1": "40 of 4,954",
        "group_2": "59 of 4,927",
        "difference": "-0.4 points",
        "interval": "-0.8 to 0.0",
        "trial_title": "Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)"
      },
      {
        "id": "NCT00135707-fef46187",
        "title": "Vitamins vs Placebo: Postpartum Pulmonary Edema",
        "summary": "3 of 4951 against 10 of 4926; risk difference -0.1 points, 95% interval -0.3 to 0.0; NCT00135707, Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)",
        "record": "/library/comparisons/NCT00135707-fef46187",
        "nct_id": "NCT00135707",
        "kind": "outcome",
        "participants": 9877,
        "risk_difference": {
          "value": -0.0014241064666783605,
          "lower": -0.0031734441539366474,
          "upper": 0.00007189114431334809
        },
        "group_1": "3 of 4,951",
        "group_2": "10 of 4,926",
        "difference": "-0.1 points",
        "interval": "-0.3 to 0.0",
        "trial_title": "Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=52",
  "request_id": "mUpkDq1NyV4Q7ZF2"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?